
The value of patient experience data in drug evaluations
Patient experience data (PED) is gaining ground with regulators. The EMA has published a draft reflection paper and the FDA has built out its Patient-Focused Drug Development framework. HTA bodies are less aligned: our review of nine markets found guidance on assessing PED uneven. For manufacturers, this creates uncertainty over which methods decision-makers will accept. Read on to find out how markets compare, which challenges keep coming up, and why your PED strategy matters







